Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals Stock Forecast

Stock Price Forecast

The 10 analysts that cover Crinetics Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $71, which forecasts a 49.79% increase in the stock price over the next year. The lowest target is $40 and the highest is $108.

Price Target: $71 (+49.79%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$40	$71	$77	$108
Change	-15.61%	+49.79%	+62.45%	+127.85%

* Price targets were last updated on Nov 7, 2025.

Analyst Ratings

The average analyst rating for Crinetics Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	4	4	4	4	4	3
Buy	5	2	6	6	6	6
Hold	1	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	7	12	12	12	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Wolleben Citizens	Citizens	Buy Maintains $143 → $108	Buy	Maintains	$143 → $108	+127.85%	Nov 7, 2025
Leland Gershell Oppenheimer	Oppenheimer	Buy Maintains $73 → $87	Buy	Maintains	$73 → $87	+83.54%	Sep 30, 2025
Jeffrey Hung Morgan Stanley	Morgan Stanley	Buy Maintains $65 → $77	Buy	Maintains	$65 → $77	+62.45%	Sep 29, 2025
Joseph Schwartz Leerink Partners	Leerink Partners	Buy Maintains $80 → $88	Buy	Maintains	$80 → $88	+85.65%	Sep 29, 2025
Richard Law Goldman Sachs	Goldman Sachs	Hold Maintains $35 → $40	Hold	Maintains	$35 → $40	-15.61%	Sep 26, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

5.46M

Increased by 425.31%

from 1.04M

Revenue Next Year

56.95M

Increased by 943.50%

from 5.46M

EPS This Year

-5.11

from -3.69

EPS Next Year

-5.40

from -5.11

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	71.00K	1.08M	4.74M	4.01M	1.04M	5.46M	56.95M
Revenue Growth	-94.05%	1,418.31%	339.43%	-15.28%	-74.11%	425.31%	943.50%
EPS	-2.42	-2.80	-3.15	-3.69	-3.69	-5.11	-5.40
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	18	17

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	10.0M	117.7M
Avg	5.5M	57.0M
Low	2.5M	24.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	863.6%	2,056.1%
Avg	425.3%	943.5%
Low	135.8%	350.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-5.09	-4.14
Avg	-5.11	-5.40
Low	-5.09	-6.90

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.